{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:15:54Z","timestamp":1792271754069,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00467-025-06960-6","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T21:53:43Z","timestamp":1760478823000},"page":"399-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishing core outcomes and minimal clinically important differences for childhood steroid sensitive nephrotic syndrome clinical trials: results from a Delphi consensus process"],"prefix":"10.1007","volume":"41","author":[{"given":"Cal H.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowrin","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlene M.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetha","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Wei","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanka Z.","family":"Vasilevska-Ristovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulan S.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"6960_CR1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-029249","volume":"148","author":"F Veltkamp","year":"2021","unstructured":"Veltkamp F, Rensma LR, Bouts AHM, LEARNS consortium (2021) Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148:e2020029249. https:\/\/doi.org\/10.1542\/peds.2020-029249","journal-title":"Pediatrics"},{"key":"6960_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"key":"6960_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ekir.2019.12.015","volume":"5","author":"SA Carter","year":"2020","unstructured":"Carter SA, Mistry S, Fitzpatrick J et al (2020) Prediction of short- and long-term outcomes in childhood nephrotic syndrome. Kidney Int Rep 5:426\u2013434. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.015","journal-title":"Kidney Int Rep"},{"key":"6960_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002290.pub6","author":"NG Larkins","year":"2024","unstructured":"Larkins NG, Hahn D, Liu ID et al (2024) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 11:CD002290.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD002290.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"6960_CR5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00467-013-2546-0","volume":"28","author":"S Samuel","year":"2013","unstructured":"Samuel S, Morgan CJ, Bitzan M et al (2013) Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatr Nephrol 28:2289\u20132298. https:\/\/doi.org\/10.1007\/s00467-013-2546-0","journal-title":"Pediatr Nephrol"},{"key":"6960_CR6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00431-021-03958-8","volume":"180","author":"AM Schijvens","year":"2021","unstructured":"Schijvens AM, van der Weerd L, van Wijk JAE et al (2021) Practice variations in the management of childhood nephrotic syndrome in the Netherlands. Eur J Pediatr 180:1885\u20131894. https:\/\/doi.org\/10.1007\/s00431-021-03958-8","journal-title":"Eur J Pediatr"},{"key":"6960_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1037\/hea0000679","volume":"38","author":"JP Troost","year":"2019","unstructured":"Troost JP, Gipson DS, Carlozzi NE et al (2019) Using PROMIS\u00ae to create clinically meaningful profiles of nephrotic syndrome patients. Health Psychol 38:410\u2013421. https:\/\/doi.org\/10.1037\/hea0000679","journal-title":"Health Psychol"},{"key":"6960_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00467-020-04684-3","volume":"36","author":"S Khullar","year":"2021","unstructured":"Khullar S, Banh T, Vasilevska-Ristovska J et al (2021) Impact of steroids and steroid-sparing agents on quality of life in children with nephrotic syndrome. Pediatr Nephrol 36:93\u2013102. https:\/\/doi.org\/10.1007\/s00467-020-04684-3","journal-title":"Pediatr Nephrol"},{"key":"6960_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jama.2014.13128","volume":"312","author":"AE McGlothlin","year":"2014","unstructured":"McGlothlin AE, Lewis RJ (2014) Minimal clinically important difference: defining what really matters to patients. JAMA 312:1342\u20131343. https:\/\/doi.org\/10.1001\/jama.2014.13128","journal-title":"JAMA"},{"key":"6960_CR10","unstructured":"United States Food and Drug Administration (2024) FDA patient-focused drug development fuidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed 10 Sept 2025"},{"key":"6960_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H et al (2017) The COMET handbook: version 1.0. Trials 18:280. https:\/\/doi.org\/10.1186\/s13063-017-1978-4","journal-title":"Trials"},{"key":"6960_CR12","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2019.01.047","volume":"95","author":"SA Carter","year":"2019","unstructured":"Carter SA, Lightstone L, Cattran D et al (2019) Standardized outcomes in nephrology\u2014glomerular disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney Int 95:1280\u20131283. https:\/\/doi.org\/10.1016\/j.kint.2019.01.047","journal-title":"Kidney Int"},{"key":"6960_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2215\/CJN.07840621","volume":"17","author":"SA Carter","year":"2022","unstructured":"Carter SA, Lightstone L, Cattran D et al (2022) A core outcome set for trials in glomerular disease: a report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) stakeholder workshops. Clin J Am Soc Nephrol 17:53\u201364. https:\/\/doi.org\/10.2215\/CJN.07840621","journal-title":"Clin J Am Soc Nephrol"},{"key":"6960_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.kint.2020.05.054","volume":"98","author":"CS Hanson","year":"2020","unstructured":"Hanson CS, Craig JC, Logeman C et al (2020) Establishing core outcome domains in pediatric kidney disease: report of the standardized outcomes in nephrology-children and adolescents (SONG-KIDS) consensus workshops. Kidney Int 98:553\u2013565. https:\/\/doi.org\/10.1016\/j.kint.2020.05.054","journal-title":"Kidney Int"},{"key":"6960_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.kint.2021.04.027","volume":"100","author":"SA Carter","year":"2021","unstructured":"Carter SA, Logeman C, Howell M et al (2021) Development of an international delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney Int 100:881\u2013893. https:\/\/doi.org\/10.1016\/j.kint.2021.04.027","journal-title":"Kidney Int"},{"key":"6960_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2215\/CJN.13101019","volume":"15","author":"SA Carter","year":"2020","unstructured":"Carter SA, Gutman T, Logeman C et al (2020) Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol 15:673\u2013684. https:\/\/doi.org\/10.2215\/CJN.13101019","journal-title":"Clin J Am Soc Nephrol"},{"key":"6960_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf118","author":"CH Robinson","year":"2025","unstructured":"Robinson CH, Ogome B-J, Selvathesan N et al (2025) Kidney function and mortality in childhood nephrotic syndrome. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaf118","journal-title":"Nephrol Dial Transplant"},{"key":"6960_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","volume":"61","author":"SR Evans","year":"2015","unstructured":"Evans SR, Rubin D, Follmann D et al (2015) Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 61:800\u2013806. https:\/\/doi.org\/10.1093\/cid\/civ495","journal-title":"Clin Infect Dis"},{"key":"6960_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","volume":"29","author":"SWX Ong","year":"2023","unstructured":"Ong SWX, Petersiel N, Loewenthal MR et al (2023) Unlocking the DOOR\u2014how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials. Clin Microbiol Infect 29:1024\u20131030. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.003","journal-title":"Clin Microbiol Infect"},{"key":"6960_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-25","volume":"14","author":"N Hussain","year":"2013","unstructured":"Hussain N, Zello JA, Vasilevska-Ristovska J et al (2013) The rationale and design of insight into nephrotic syndrome: investigating genes, health and therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome. BMC Nephrol 14:25. https:\/\/doi.org\/10.1186\/1471-2369-14-25","journal-title":"BMC Nephrol"},{"key":"6960_CR21","unstructured":"SONG Initiative (2017) The SONG Handbook. Standardised Outcomes in Nephrology (SONG) initiative, Sydney, Australia. https:\/\/songinitiative.org\/reports-and-publications\/. Accessed 10 Sept 2025"},{"key":"6960_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cptl.2018.03.019","volume":"10","author":"A Castleberry","year":"2018","unstructured":"Castleberry A, Nolen A (2018) Thematic analysis of qualitative research data: is it as easy as it sounds? Curr Pharm Teach Learn 10:807\u2013815. https:\/\/doi.org\/10.1016\/j.cptl.2018.03.019","journal-title":"Curr Pharm Teach Learn"},{"key":"6960_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4337\/jqrt.2023.0006","volume":"3","author":"PA Christou","year":"2022","unstructured":"Christou PA (2022) How to use thematic analysis in qualitative research. Journal of Qualitative Research in Tourism 3:79\u201395. https:\/\/doi.org\/10.4337\/jqrt.2023.0006","journal-title":"Journal of Qualitative Research in Tourism"},{"key":"6960_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152068","volume":"56","author":"P Brogan","year":"2022","unstructured":"Brogan P, Naden R, Ardoin SP et al (2022) The pediatric glucocorticoid toxicity index. Semin Arthritis Rheum 56:152068. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152068","journal-title":"Semin Arthritis Rheum"},{"key":"6960_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"6960_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.20233411S1256a","volume":"34","author":"E Salmon","year":"2023","unstructured":"Salmon E, Sifre K, Hurt CN et al (2023) Development of a Patient-Reported Outcome for Older Children and Adults with Nephrotic Syndrome as Part of \u201cPreparing a Clinical Outcomes Set for Nephrotic Syndrome\u201d (Prepare-NS). J Am Soc Nephrol 34:256\u2013256. https:\/\/doi.org\/10.1681\/ASN.20233411S1256a","journal-title":"J Am Soc Nephrol"},{"key":"6960_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1681\/ASN.20223311S1797b","volume":"33","author":"E Salmon","year":"2022","unstructured":"Salmon E, Gipson D, Carlozzi NE et al (2022) Preparing a clinical outcomes assessment set for nephrotic syndrome (Prepare-NS): a new core set of clinical outcome assessments focused on fluid overload for nephrotic syndrome: SA-PO705. J Am Soc Nephrol 33:797\u2013797. https:\/\/doi.org\/10.1681\/ASN.20223311S1797b","journal-title":"J Am Soc Nephrol"},{"key":"6960_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000531505","volume":"3","author":"DS Gipson","year":"2023","unstructured":"Gipson DS, Pal M, Desmond H et al (2023) Developing an edema clinician-reported outcome measure for nephrotic syndrome. Glomerular Dis 3:132\u2013139. https:\/\/doi.org\/10.1159\/000531505","journal-title":"Glomerular Dis"},{"key":"6960_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.ajkd.2018.12.040","volume":"74","author":"CS Hanson","year":"2019","unstructured":"Hanson CS, Gutman T, Craig JC et al (2019) Identifying important outcomes for young people with CKD and their caregivers: a nominal group technique study. Am J Kidney Dis 74:82\u201394. https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.040","journal-title":"Am J Kidney Dis"},{"key":"6960_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2215\/CJN.0000000000000467","volume":"19","author":"M Matsuda-Abedini","year":"2024","unstructured":"Matsuda-Abedini M, Zappitelli M, Widger K et al (2024) Validation of patient-reported outcome measure in pediatric CKD (PRO-Kid). Clin J Am Soc Nephrol 19:851\u2013859. https:\/\/doi.org\/10.2215\/CJN.0000000000000467","journal-title":"Clin J Am Soc Nephrol"},{"key":"6960_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05393-4","volume":"22","author":"T Kristensen","year":"2021","unstructured":"Kristensen T, Birn H, Ivarsen P (2021) A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN). Trials 22:442. https:\/\/doi.org\/10.1186\/s13063-021-05393-4","journal-title":"Trials"},{"key":"6960_CR32","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00467-021-05048-1","volume":"36","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Mishra K, Kumar M (2021) Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial. Pediatr Nephrol 36:3143\u20133150. https:\/\/doi.org\/10.1007\/s00467-021-05048-1","journal-title":"Pediatr Nephrol"},{"key":"6960_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.kint.2024.01.028","volume":"105","author":"A Sinha","year":"2024","unstructured":"Sinha A, Devi KG, Kalra S et al (2024) An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. Kidney Int 105:1113\u20131123. https:\/\/doi.org\/10.1016\/j.kint.2024.01.028","journal-title":"Kidney Int"},{"key":"6960_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018148","volume":"7","author":"AM Schijvens","year":"2017","unstructured":"Schijvens AM, Dorresteijn EM, Roeleveld N et al (2017) Reducing STEroids in relapsing nephrotic syndrome: the RESTERN study\u2014protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 7:e018148. https:\/\/doi.org\/10.1136\/bmjopen-2017-018148","journal-title":"BMJ Open"},{"key":"6960_CR35","doi-asserted-by":"publisher","first-page":"e1633","DOI":"10.1212\/WNL.0000000000207684","volume":"101","author":"JM Chamberlain","year":"2023","unstructured":"Chamberlain JM, Kapur J, Silbergleit RS et al (2023) Desirability of outcome ranking for status epilepticus: a benefit-risk approach to design and analyses of clinical SE trials. Neurology 101:e1633\u2013e1639. https:\/\/doi.org\/10.1212\/WNL.0000000000207684","journal-title":"Neurology"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06960-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:02:07Z","timestamp":1766523727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06960-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["6960"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06960-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}